CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ARGX

Empasiprubart IV

Phase 3
argenx SE (ARGX)

Phase 3

Development Phase

2

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Oct '27
ARGXPhase 2

Empasiprubart IV Phase 2 Est. Readout (ADAPT Forward2)

Empasiprubart IV
Oct 2027~
CT.gov
00%
Q4 '27
ARGXPhase 3

Empasiprubart IV Phase 3 Est. Readout (emnergize)

Empasiprubart IV
Q4 2027~Q
CT.gov
00%
Development History
Nov '26
ARGXPhase 2

Empasiprubart IV Phase 2 Est. Readout (empacific)

Empasiprubart IV
Nov 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Chronic Inflammatory Demyelinating Polyneuropathy

View Full Landscape
Drug Information

Target Indication

Chronic Inflammatory Demyelinating Polyneuropathy

Clinical Trial

NCT07091630

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.